文献速递胸部技术与安全PETCT

非癌肺FDG高摄取预测肺癌免疫治疗不良反应与预后

High FDG Uptake in the Non-cancerous Lung Predicts Immune-Related Adverse Events and Poor Prognosis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors.
PubMed 文献 · Acad Radiol · 2026-07-28

本研究回顾性分析165例接受免疫检查点抑制剂治疗前完成PET/CT的肺癌患者,采用AI分割非癌侧肺并以SUV≥1.0区域的平均SUV与肺容积计算总糖酵解活性NCL-TGA1.0。结果显示NCL-TGA1.0高者免疫相关不良事件风险升高,在84例不可切除非小细胞肺癌中无进展生存期与总生存期均显著缩短。

要点

  • 治疗前PET/CT上非癌侧肺FDG摄取增高提示免疫相关不良事件风险增加。
  • 不可切除非小细胞肺癌中非癌肺高摄取者中位无进展生存期与总生存期明显较短
  • 非癌肺FDG摄取可作为ICI治疗前影像分层指标,帮助识别高风险患者。

核心结论

  • 非癌肺FDG高摄取是肺癌患者接受ICI治疗后发生irAE及生存不良的预测因素。

研究设计与样本

  • 回顾性研究,纳入165例ICI治疗前行PET/CT的肺癌患者,其中84例为不可切除非小细胞肺癌用于生存分析。
  • 应用AI分割对侧无转移的非癌肺,以SUV≥1.0区域的平均SUV与肺容积乘积计算NCL-TGA1.0。
  • 参考标准为临床随访判定的免疫相关不良事件及生存结局,采用多因素分析和Kaplan-Meier法评估。

关键影像表现/征象

  • 非癌侧肺FDG摄取增高可表现为治疗前PET/CT上NCL-TGA1.0≥149.45。
  • FDG摄取增高位于原发肿瘤对侧且无转移病灶的肺组织,需AI分割自动量化。

诊断标准与关键数值

  • NCL-TGA1.0≥149.45定义为高摄取,是发生irAE的独立相关因素(OR=6.910,p=0.005)。
  • 高NCL-TGA1.0与非ILD类irAE风险增加相关(OR=4.244,p=0.020)。
  • 84例不可切除非小细胞肺癌中,高NCL-TGA1.0者中位无进展生存期4.30个月,对照为9.90个月(p=0.007)。
  • 高NCL-TGA1.0者中位总生存期6.93个月,对照为22.03个月(p=0.029)。

临床应用与阅片要点

  • ICI治疗前PET/CT除评估肿瘤负荷外,应留意对侧非癌肺FDG摄取水平,提示irAE风险。
  • 报告可描述非癌肺SUV≥1.0区域的代谢容积与平均SUV,必要时计算NCL-TGA1.0辅助分层。
  • 高NCL-TGA1.0者后续随访需警惕免疫相关不良事件并缩短影像复查间隔。

局限性

  • 回顾性单中心设计,存活分析仅纳入84例不可切除非小细胞肺癌患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Immune checkpoint inhibitors (ICIs) have improved survival in non-small cell lung cancer (NSCLC); however, predicting immune-related adverse events (irAEs) remains a clinical challenge. We previously showed that high 18F-fluorodeoxyglucose (18F-FDG) uptake in the non-cancerous lung (NCL) on PET/CT is associated with the risk of interstitial lung disease. This study further investigated whether NCL FDG uptake predicts the risk of irAEs, including both ILD and non-ILD events, as well as survival outcomes in patients with lung cancer receiving ICIs.

MATERIALS AND METHODS: We retrospectively analyzed 165 patients with lung cancer who underwent PET/CT before ICI therapy. FDG uptake in the NCL, defined as the lung contralateral to the primary tumor and free of metastatic lesions, was quantified using AI-based segmentation. Total glycolytic activity in the NCL (NCL-TGA1.0) was calculated as the product of the mean SUV and the lung volume, both measured within regions with SUV ≥1.0. Associations of NCL-TGA1.0 with irAE incidence and survival outcomes were assessed using multivariable and Kaplan-Meier analyses.

RESULTS: High NCL-TGA1.0 (≥149.45) was independently associated with increased risk of irAEs in multivariate analysis (odds ratio [OR]: 6.910; p=0.005), including non-ILD irAEs (OR: 4.244; p=0.020). In survival analysis of 84 unresectable NSCLC patients, high NCL-TGA1.0 was associated with significantly shorter progression-free survival (median: 4.30 vs. 9.90 months, p=0.007) and overall survival (median: 6.93 vs. 22.03 months, p=0.029).

CONCLUSION: High FDG uptake in the NCL is a predictor of irAEs and poor survival in patients with lung cancer receiving ICIs. These results may help to identify high-risk patients prior to treatment.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Yamazaki, Watanabe, Tominaga, et al. High FDG Uptake in the Non-cancerous Lung Predicts Immune-Related Adverse Events and Poor Prognosis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors. Acad Radiol. 2026. PMID: 42509051. doi:10.1016/j.acra.2026.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。